TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.76M | 1.40M | 1.66M | 951.70K | 1.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.24M | 4.56M | 4.22M | 3.17M | 5.09M |
| Operating Income | -7.24M | -4.56M | -4.22M | -3.17M | -5.09M |
| Income Before Tax | -13.22M | -4.86M | -4.28M | -12.09M | -5.92M |
| Income Tax Expenses | 226.10K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.44M | -4.86M | -4.28M | -12.09M | -5.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.44M | -4.86M | -4.28M | -12.09M | -5.92M |
| EBIT | -7.24M | -4.56M | -4.22M | -3.17M | -5.09M |
| EBITDA | -7.19M | -4.56M | -4.21M | -3.16M | -5.08M |
| EPS Basic | -16.49 | -5.82 | -5.13 | -70.16 | -281.24 |
| Normalized Basic EPS | -4.12 | -3.64 | -3.21 | -43.85 | -174.89 |
| EPS Diluted | -16.49 | -5.82 | -5.13 | -70.16 | -281.24 |
| Normalized Diluted EPS | -4.12 | -3.64 | -3.21 | -43.85 | -174.89 |
| Average Basic Shares Outstanding | 913.10K | 833.70K | 833.70K | 172.30K | 21.10K |
| Average Diluted Shares Outstanding | 913.10K | 833.70K | 833.70K | 172.30K | 21.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |